Létrozole and Lipid Profile

Introduction to Létrozole's Effects on Lipids

The American Society of Clinical Oncology recommends monitoring serum cholesterol levels in patients undergoing letrozole treatment, as letrozole may increase cholesterol levels, particularly in the first months of treatment 1, 2
Patients on letrozole often present with multiple concurrent cardiovascular risk factors, including obesity, metabolic syndrome, age, diet, and lack of physical activity, which are common to both cardiovascular disease and breast cancer 1, 2

The National Comprehensive Cancer Network recommends establishing a baseline lipid profile before initiating letrozole, then monitoring regularly, including measuring total cholesterol, HDL, LDL, and triglycerides before treatment 1, 2
Evaluating other cardiovascular risk factors, such as hypertension, diabetes, and obesity, is crucial because they are frequent in breast cancer survivors 1, 2

Letrozole has a significantly LOWER thromboembolic risk compared to tamoxifen, despite its potential effects on cholesterol, with a higher incidence of grade 3-5 thromboembolic events associated with tamoxifen 3, 4